New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
14:36 EDTAKRXAkorn sees 2013 gross margins 54%-56%
Overall gross margins for 2013 are expected to be in the range of 54%-56% as a result of growth from lower margin new products that are either partnered with shared economics, in-licensed or are contract manufactured for Akorn. The vast majority of Akorn's active pipeline will be manufactured by Akorn with no partnering or shared economics and as a result are expected to have significantly higher margins than the products contributing to growth in 2013. Additionally, we expect improvement in the margins on our more competitive products once we achieve U.S. FDA approval of our Indian manufacturing site.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:51 EDTAKRXS&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
Subscribe for More Information
17:22 EDTAKRXUnited Insurance to replace Akorn in S&P 600 as of 1/30 close
17:21 EDTAKRXAkorn to replace Protective Life in S&P 400 as of 1/30 close
Subscribe for More Information
January 26, 2015
07:05 EDTAKRXAkorn price target raised to $55 from $45 at Piper Jaffray
Piper Jaffray raised its price target for Akorn shares to $55 saying approvals of "seemingly minor" abbreviated New Drug Application opportunities, like last week's Phenylephrine Hydrochloride Ophthalmic Solution, could in the aggregate drive significant upside to consensus estimates in 2015 and beyond. Piper reiterates an Overweight rating on shares of Akorn.
January 20, 2015
08:09 EDTAKRXAkorn price target raised to $49 from $44 at Jefferies
Jefferies raised its price target for Akorn shares to $49 to reflect its FY15 estimates. The firm keeps a Buy rating on the stock.
07:11 EDTAKRXAkorn receives FDA approval for Phenylephrine Hydrochloride Ophthalmic Solution
Subscribe for More Information
January 15, 2015
17:36 EDTAKRXAkorn's generic Durezol patent challenged
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use